SEARCH

SEARCH BY CITATION

References

  • 1
    Semenova EA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: update and perspectives. Adv Pharmacol 2008; 56: 199228.
  • 2
    Garrido C, Soriano V, de Mendoza C. New therapeutic strategies for raltegravir. J Antimicrob Chemother 2010; 65: 218223.
  • 3
    Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605612.
  • 4
    Lennox JL, DeJesus E, Berger DS et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 3948.
  • 5
    Ceccherini-Silberstein F, Malet I, Fabeni L et al. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 2010; 65: 23052318.
  • 6
    Varghese V, Liu TF, Rhee SY et al. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010; 26: 13231326.
  • 7
    Margeridon-Thermet S, Shafer RW. Comparison of the mechanisms of drug resistance among HIV, Hepatitis B, and Hepatitis C. Viruses 2010; 2: 26962739.
  • 8
    Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764774.
  • 9
    Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83: 1144011446.
  • 10
    da Silva D, Van Wesenbeeck L, Breilh D et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010; 65: 12621269.
  • 11
    Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 2010; 54: 934936.
  • 12
    Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; 67: 24942500.
  • 13
    Blanco JL, Martinez-Picado J. HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS 2012; 7: 415421.
  • 14
    Zazzi M, Prosperi M, Vicenti I et al. Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother 2009; 64: 616624.
  • 15
    Johnson VA, Calvez V, Günthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156164.
  • 16
    Eron J, Rockstroh J, Reynes J et al. QDMRK, a phase III study of the safety and efficacy of once daily vs twice daily RAL in combination therapy for treatment-naive HIV-infected patients. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; February 27–March 2, 2011; Boston, Massachusetts. Abstract 150LB.
  • 17
    Lazzarin A, Dejesus E, Rockstroh J et al. Durable and consistent efficacy of raltegravir (RAL) with tenofovir (TDF) and emtricitabine (FTC) across demographic and baseline prognostic factors in treatment-naïve patients (pts) from STARTMRK at Wk 156. Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2011; Chicago, Illinois. Abstract H2-790.
  • 18
    Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53: 696699.
  • 19
    Hatano H, Lampiris H, Fransen S et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J AIDS 2010; 54: 398393.
  • 20
    Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355365.
  • 21
    Rhee SY, Fessel WJ, Liu TF et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009; 200: 453463.
  • 22
    Malet I, Fourati S, Morand-Joubert L et al. Risk factors for raltegravir resistance development in clinical practice. J Antimicrob Chemother 2012; 61: 297301.
  • 23
    Zaccarelli M, Lorenzini P, Marconi P et al. Is extended resistance to the historical antiretroviral drugs and drug classes still a risk factor for HIV progression [abstract P138]. In: Program and abstracts of the Tenth International Congress on Drug Therapy in HIV Infection, 7–11 November 2010, Glasgow, UK, 2010:66.
  • 24
    Ferns RB, Kirk S, Bennett J, Williams I, Edwards S, Pillay D. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009; 23: 21592164.
  • 25
    Garrido C, Geretti AM, Zahonero N et al. Integrase variability and susceptibility to integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010; 65: 320326.
  • 26
    Codoñer FM, Pou C, Thielen A et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 2010; 88: 281286.
  • 27
    Charpentier C, Laureillard D, Piketty C et al. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010; 24: 867873.
  • 28
    Liu J, Miller MD, Danovich RM et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 2011; 55: 11141119.
  • 29
    Ceccherini-Silberstein F, Van Baelen K, Armenia D et al. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 2010; 54: 39383948.